Natural Products for the Treatment of Post-stroke Depression

Chaoyou Fang,Zeyu Zhang,Houshi Xu,Yibo Liu,Xiaoyu Wang,Ling Yuan,Yuanzhi Xu,Zhengyang Zhu,Anke Zhang,Anwen Shao,Meiqing Lou
DOI: https://doi.org/10.3389/fphar.2022.918531
IF: 5.6
2022-05-30
Frontiers in Pharmacology
Abstract:Post-stroke depression (PSD) is the most frequent and important neuropsychiatric consequence of stroke. It is strongly associated with exacerbated deterioration of functional recovery, physical and cognitive recoveries, and quality of life. However, its mechanism is remarkably complicated, including the neurotransmitters hypothesis (which consists of a monoaminergic hypothesis and glutamate-mediated excitotoxicity hypothesis), inflammation hypothesis, dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, and neurotrophic hypothesis and neuroplasticity. So far, the underlying pathogenesis of PSD has not been clearly defined yet. At present, selective serotonin reuptake inhibitors (SSRIs) have been used as the first-line drugs to treat patients with PSD. Additionally, more than SSRIs, a majority of the current antidepressants complied with multiple side effects, which limits their clinical application. Currently, a wide variety of studies revealed the therapeutic potential of natural products in the management of several diseases, especially PSD, with minor side effects. Accordingly, in our present review, we aim to summarize the therapeutic targets of these compounds and their potential role in-clinic therapy for patients with PSD.
pharmacology & pharmacy
What problem does this paper attempt to address?